GNI : Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status
October 03, 2022 at 02:44 am EDT
Share
October 3rd, 2022
Company Name:
GNI Group Ltd.
Representative:
Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
(Security Code: 2160, TSE Growth)
Contact Person:
General Manager,
Business Management Department
Akihiro Nakano
(TEL. 03-6214-3600)
Monthly Update on the 47th Series Stock Acquisition Rights (Moving Strike Warrants) Exercise Status
With regards to the 47th Series Stock Acquisition Rights (Moving Strike Warrants, hereinafter referred to as "Rights") issued by GNI Group Ltd., on February 25, 2021, the Group reports the status of exercise for September 2022 as follows:
(1) Name of the Warrants
GNI Group Ltd. 47th Series Stock
Acquisition Rights
(2) Shared delivered during the applicable month
0 Shares
(3) Number of Rights exercised during applicable month and ratio of
0 Rights (0% of total Rights issued)
exercised Rights to total Rights issued
(4) Number of unexercised Rights as of the end of the month preceding
16,449 Rights
the applicable month
(5) Number of unexercised Rights as of the end of the applicable month
16,449 Rights
(6) Exercise status during the applicable month 2022 September 1 (Thu) - September 30 (Fri)
Shares delivered
Exercise
Total number of
Exercise Date
exercised Rights
New issues
Transferred
Price (JPY)
treasury stock
From September 01
(Thu)- September 07(Wed)
0
0
1,404
0
From September 08
(Thu)- September 14(Wed)
0
0
1,302
0
From September 15
(Thu)- September 21(Wed)
0
0
1,273
0
From September 22
(Thu)- September 30(Fri)
0
0
1,203
0
Status of Compliance with limitations on exercise in pursuant to the Tokyo Stock Exchange's "Securities Listing Regulations" Article 434
[1] Cumulative number of shares
[2] Shares outstanding as of the
[3] Exercise ratio ([1]/[2])(%) (subject
delivered (shares)
date of issuance of the Rights
to stipulated exercise limit)
0
45,887,943
0
Attachments
Original Link
Original Document
Permalink
Disclaimer
GNI Group Limited published this content on 03 October 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 October 2022 06:43:03 UTC.
GNI Group Ltd is a Japan-based company engaged in pharmaceutical business and medical device business. The Company conducts global pharmaceutical research and development, manufacturing and distribution and biomaterials business. The Company operates in two business segments. The Pharmaceuticals segment conducts research and development, manufacturing, and sale of developed compounds, including ETUARY sold in the China market and Hydronidone (F351), which is in clinical trials. The main products also include other pharmaceuticals and reagents. The Medical Devices segment develops, manufactures, and sells medical devices such as biomaterials in the United States. This segment also includes medical device Designated Marketing Authorization Holder (DMAH) and In-Country Caretaker (ICC) services. The Company also conducts clinical and business development in the United States and conducts clinical development of F351 for Metabolic Dysfunction-Associated Steatohepatitis in the United States.
GNI GROUP LTD. 
